Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ALX Oncology HoldingsALXO +2.02%31 3-1 Month Momentum % is 2.53% as of Aug. 25, 2026. GuruFocus rates ALXO with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,389 Biotechnology companies, ALX Oncology Holdings ranks better than 70.91% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-25), ALX Oncology Holdings's 3-1 Month Momentum % is 2.53%.
The industry rank for ALX Oncology Holdings's 3-1 Month Momentum % or its related term are showing as below:
ALXO's 3-1 Month Momentum % is ranked better than 70.91% of 1389
companies
in the Biotechnology industry
Industry Median: -9.61
vs ALXO: 2.53
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ALX Oncology Holdings 3-1 Month Momentum % Related Terms
ALXO vs CYDY, BCYC, ELDN: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, ALX Oncology Holdings's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (ALXO) has a 3-1 Month Momentum % of 2.53% as of Aug. 25, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ALX Oncology Holdings and its competitors. According to the industry distribution chart, ALX Oncology Holdings ranks #404 out of 1389 companies in the Biotechnology industry, placing it in the top 29.1%.
Is ALX Oncology Holdings' 3-1 Month Momentum % too high?
ALX Oncology Holdings' current 3-1 Month Momentum % is 2.53%. Based on the distribution chart, ALX Oncology Holdings ranks #404 out of 1389 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ALX Oncology Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' 3-1 Month Momentum % compare to CYDY and BCYC?
According to the Biotechnology industry distribution chart, ALX Oncology Holdings ranks #404 out of 1389 companies for 3-1 Month Momentum %. This puts ALX Oncology Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ALX Oncology Holdings and its competitors. ALX Oncology Holdings's current 3-1 Month Momentum % is 2.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current 3-1 Month Momentum % of 2.53%. The current 3-1 Month Momentum % is 2.53%. ALX Oncology Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current 3-1 Month Momentum % is 2.53% as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score
Get the complete analysis for ALXO
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALXO has been successfully added to your 
